ISPOR’s 1st PLENARY OF 18th ANNUAL EUROPEAN CONGRESS FOCUSES ON LIFECYCLE APPROACH TO DECISION MAKING ON HEALTH TECHNOLOGIES

Published Nov 9, 2015
Milan, Italy—November 9, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress first plenary session — Strategy in Motion: The Current and Future Lifecycle Approach to Decision Making on Health Technologies — was held this morning at the MiCo – Milano Congressi in Milan, Italy. The plenary was moderated by François Meyer, MD, Advisor to the President, International Affairs, French National Authority for Health (HAS), Saint-Denis La Plaine, France and featured speakers:

- Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency (EMA), London, UK

- Jerome Boehm, Team Leader, Health Technology Assessment, Directorate-General for Health and Food Safety, European Commission, Brussels, Belgium - Finn Børlum Kristensen, MD, PhD, Professor, Health Services Research & Health Technology Assessment, University of Southern Denmark and Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark - Mirella Marlow, MA, MBA, Programme Director, Devices and Diagnostics Systems, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK The Strategy in Motion plenary focused on the work underway within the Adaptive Pathways to Patients initiative for drugs. The panel presented their views on adaptive pathways as the preferred approach to developing, licensing, assessing, appraising, and paying for new medicines and treatments. The panel also examined the European Commission's health technology assessment (HTA) network plans following the transition of the successful EUnetHTA program, which built strength and dialogue both across Europe and globally. Released presentations from the ISPOR 18th Annual European Congress are available at http://www.ispor.org/Event/ReleasedPresentations/2015Milan. ISPOR’s 18th Annual European Congress may be followed on social media using the hashtag #ISPORMilan.

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×